A New Long-Lasting RNA Treatment for Bleeding Disorders
Official title: Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy
Funded at Versiti Blood Health, INC. · NIH-11132938 · Data updated 2026-11-12
This work explores how blood clot breakdown contributes to bleeding and aims to create a new, long-acting RNA medicine to help people with bleeding disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Blood Health, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $718,283 |
| NIH project number | 5R01HL166382-03 |
| Project ID | NIH-11132938 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is ultimately aimed at helping patients with diagnosed or undiagnosed bleeding disorders who experience increased bleeding due to issues with clot breakdown.
✕Less likely to help
Patients whose bleeding is not primarily caused by excessive clot breakdown (fibrinolysis) may not receive direct benefit from this specific therapy.
What this research studies
For individuals with bleeding disorders or severe injuries, the body's ability to form and break down blood clots can be out of balance, leading to increased bleeding. Current medicines often aren't enough, especially for long-term prevention, because they don't last very long in the body. Our goal is to develop a new type of RNA therapy that can reduce bleeding over a longer period by targeting a key protein involved in dissolving clots. This new medicine would be delivered using a safe, clinically approved method, offering a more effective way to manage bleeding for many patients.
Why it matters
Potential benefit: If successful, this new long-acting RNA therapy could provide a more effective and convenient way to prevent and manage bleeding for individuals with various bleeding disorders.
How similar studies have gone: While current antifibrinolytic drugs exist, this approach focuses on a novel long-acting RNA therapy, which represents a new direction for managing bleeding disorders.
Where this research is happening
-
Versiti Blood Health, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Kastrup, Christian — Versiti Blood Health, INC.
- Study coordinator: Kastrup, Christian
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.